Latest Insider Transactions at Cullinan Oncology, Inc. (CGEM)
This section provides a real-time view of insider transactions for Cullinan Oncology, Inc. (CGEM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cullinan Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cullinan Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 18
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
394
-0.67%
|
$3,152
$8.76 P/Share
|
|
May 18
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
399
-0.46%
|
$3,192
$8.76 P/Share
|
|
May 12
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
193
-0.21%
|
$1,544
$8.78 P/Share
|
|
May 12
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
347
-0.4%
|
$2,776
$8.78 P/Share
|
|
Apr 25
2023
|
Nadim Ahmed President and CEO |
SELL
Open market or private sale
|
Direct |
716
-0.61%
|
$7,160
$10.59 P/Share
|
|
Apr 18
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
392
-0.66%
|
$3,920
$10.71 P/Share
|
|
Apr 18
2023
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
290
-0.62%
|
$2,900
$10.71 P/Share
|
|
Apr 18
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
238
-0.26%
|
$2,380
$10.71 P/Share
|
|
Apr 18
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
398
-0.45%
|
$3,980
$10.71 P/Share
|
|
Apr 12
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
318
-0.36%
|
$3,180
$10.22 P/Share
|
|
Apr 12
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
176
-0.19%
|
$1,760
$10.22 P/Share
|
|
Mar 23
2023
|
Nadim Ahmed President and CEO |
SELL
Open market or private sale
|
Direct |
706
-0.59%
|
$7,060
$10.51 P/Share
|
|
Mar 20
2023
|
Jacquelyn L Sumer Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
305
-0.65%
|
$3,355
$11.32 P/Share
|
|
Mar 20
2023
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
238
-0.26%
|
$2,618
$11.32 P/Share
|
|
Mar 20
2023
|
Jeffrey Alan Jones Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
390
-0.65%
|
$4,290
$11.32 P/Share
|
|
Mar 20
2023
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
399
-0.45%
|
$4,389
$11.32 P/Share
|
|
Feb 22
2023
|
Nadim Ahmed President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
109,000
+47.87%
|
-
|
|
Feb 17
2023
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+34.71%
|
-
|
|
Feb 17
2023
|
Jacquelyn L Sumer Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,000
+50.0%
|
-
|
|
Feb 17
2023
|
Corrine Savill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,500
+10.75%
|
-
|
|
Feb 17
2023
|
Jeffrey Alan Jones Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+50.0%
|
-
|
|
Feb 17
2023
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,500
+29.61%
|
-
|
|
Feb 17
2023
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,500
+33.62%
|
-
|
|
Jan 19
2023
|
Bvf Partners L P > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
6,400,000
-85.16%
|
-
|
|
Dec 30
2022
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
201
+0.48%
|
$1,608
$8.97 P/Share
|
|
Nov 25
2022
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.01%
|
$52,000
$13.3 P/Share
|
|
Nov 25
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+6.55%
|
$16,000
$4.3 P/Share
|
|
Sep 27
2022
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.01%
|
$48,000
$12.4 P/Share
|
|
Sep 27
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+6.55%
|
$16,000
$4.3 P/Share
|
|
Aug 08
2022
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,385
-2.55%
|
$20,775
$15.01 P/Share
|
|
Aug 08
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,385
+2.48%
|
$5,540
$4.3 P/Share
|
|
Aug 04
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,989
-2.03%
|
$363,846
$14.31 P/Share
|
|
Aug 03
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
19,129
-1.47%
|
$267,806
$14.24 P/Share
|
|
Aug 02
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,792
-0.37%
|
$67,088
$14.1 P/Share
|
|
Jul 25
2022
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,000
-13.11%
|
$112,000
$14.51 P/Share
|
|
Jul 25
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+11.59%
|
$32,000
$4.3 P/Share
|
|
Jul 19
2022
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
14,958
-9.09%
|
$224,370
$15.22 P/Share
|
|
Jul 18
2022
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,042
-2.97%
|
$75,630
$15.06 P/Share
|
|
Jul 11
2022
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
40,000
-9.55%
|
$520,000
$13.59 P/Share
|
|
Jun 30
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,620
+2.96%
|
$16,200
$10.9 P/Share
|
|
Jun 30
2022
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,451
+3.4%
|
$14,510
$10.9 P/Share
|
|
Jun 30
2022
|
Nadim Ahmed President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,620
+14.3%
|
$16,200
$10.9 P/Share
|
|
Jun 24
2022
|
Morana Jovan Embiricos > 10% Shareholder |
SELL
Payment of exercise price or tax liability
|
Direct |
45,078
-17.83%
|
$586,014
$13.39 P/Share
|
|
Jun 24
2022
|
Morana Jovan Embiricos > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
140,374
+22.43%
|
$561,496
$4.3 P/Share
|
|
Jun 23
2022
|
F2 Bioscience I 2017 LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
29,631
-5.23%
|
$385,203
$13.0 P/Share
|
|
Jun 22
2022
|
F2 Bioscience I 2017 LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
49,953
-8.1%
|
$599,436
$12.7 P/Share
|
|
Jun 21
2022
|
F2 Bioscience I 2017 LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
22,319
-3.49%
|
$267,828
$12.77 P/Share
|
|
Jun 06
2022
|
Nadim Ahmed President and CEO |
BUY
Open market or private purchase
|
Direct |
8,090
+50.0%
|
$97,080
$12.4 P/Share
|
|
Jun 01
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
751,396
+9.72%
|
$8,265,356
$11.0 P/Share
|
|
May 16
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
35,158
-2.62%
|
$386,738
$11.23 P/Share
|